DexCom, Inc. (DXCM)

Market Cap	28.11B -15.5%
Revenue (ttm)	4.82B +16.2%
Net Income	930.40M +73.8%
EPS	2.34 +75.5%
Shares Out	385.87M
PE Ratio	31.16
Forward PE	27.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,859,299
Open	73.47
Previous Close	72.59
Day's Range	72.52 - 75.44
52-Week Range	54.11 - 89.98
Beta	1.44
Analysts	Strong Buy
Price Target	83.00 (+13.92%)
Earnings Date	Apr 30, 2026

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 14, 2005
• Employees: 11,100
• Stock Exchange: NASDAQ
• Ticker Symbol: DXCM
• Website: https://www.dexcom.com

Financial Performance

In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.

Analyst Summary

According to 27 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price target is $83.0, which is an increase of 13.92% from the latest price.

Price Target

$83.0

(13.92% upside)

Analyst Consensus: Strong Buy